$IRWD
IRONWOOD PHARMACEUTICALS INC Stock $irwd

$irwd Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000155837023008092 Filed on May 04, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$107.4M	$104.1M	$97.53M
YoY Change	10.44%	6.7%	9.77%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$52.48M	$31.12M	$28.86M
YoY Change	74.23%	7.82%	4.37%
% of Gross Profit
Research & Development	$34.58M	$12.85M	$10.82M
YoY Change	201.93%	18.71%	-30.11%
% of Gross Profit
Depreciation & Amortization	$270.0K	$286.0K	$355.0K
YoY Change	-25.0%	-19.44%	-13.41%
% of Gross Profit
Operating Expenses	$87.06M	$43.96M	$39.68M
YoY Change	109.4%	10.79%	-8.66%
Operating Profit	-$1.083B	$60.10M	$57.85M
YoY Change	-2046.17%	3.89%	27.42%
Interest Expense	$1.840M	$1.527M	$2.341M
YoY Change	-16.63%	-34.77%	-69.3%
% of Operating Profit		2.54%	4.05%
Other Income/Expense, Net	$6.917M	$5.764M	-$1.381M
YoY Change	-469.89%	-517.38%	-72.6%
Pretax Income	-$1.076B	$65.86M	$56.47M
YoY Change	-2100.97%	16.64%	39.91%
Income Tax	$13.30M	$20.10M	$17.70M
% Of Pretax Income		30.52%	31.35%
Net Earnings	-$1.062B	$45.71M	$38.80M
YoY Change	-2964.58%	17.82%	-2.82%
Net Earnings / Revenue	-989.17%	43.93%	39.78%
Basic Earnings Per Share	-$6.84	$0.30	$0.25
Diluted Earnings Per Share	-$6.84	$0.25	$0.21
COMMON SHARES
Basic Shares Outstanding	155.3M	154.2M	157.8M
Diluted Shares Outstanding	155.4M	186.7M	189.5M

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$175.3M	$740.3M	$593.4M
YoY Change	-65.24%	24.77%	35.32%
Cash & Equivalents	$175.3M	$740.3M	$593.4M
Short-Term Investments
Other Short-Term Assets	$23.29M	$10.28M	$11.22M
YoY Change	109.73%	-8.31%	-10.99%
Inventory
Prepaid Expenses
Receivables	$119.0M	$115.7M	$105.5M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$317.6M	$866.4M	$710.1M
YoY Change	-48.59%	22.01%	31.93%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.876M	$6.015M	$7.229M
YoY Change	-15.62%	-16.79%	-14.96%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.920M	$820.0K	$955.0K
YoY Change	349.54%	-14.14%	3.35%
Total Long-Term Assets	$285.6M	$288.9M	$373.3M
YoY Change	-20.19%	-22.6%	510.95%
TOTAL ASSETS
Total Short-Term Assets	$317.6M	$866.4M	$710.1M
Total Long-Term Assets	$285.6M	$288.9M	$373.3M
Total Assets	$603.2M	$1.155B	$1.083B
YoY Change	-38.18%	6.64%	80.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.505M	$118.0K	$532.0K
YoY Change	1005.68%	-77.82%	-36.82%
Accrued Expenses	$96.16M	$23.73M	$25.39M
YoY Change	321.2%	-6.56%	11.36%
Deferred Revenue	$1.500M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$199.1M		$120.7M
YoY Change
Total Short-Term Liabilities	$305.4M	$23.84M	$147.4M
YoY Change	1210.8%	-83.82%	524.51%
LONG-TERM LIABILITIES
Long-Term Debt	$598.0M	$396.7M	$395.1M
YoY Change	51.21%	0.41%	-9.41%
Other Long-Term Liabilities	$31.04M	$11.82M	$5.111M
YoY Change	378.12%	131.34%	213.56%
Total Long-Term Liabilities	$31.04M	$11.82M	$5.111M
YoY Change	378.12%	131.34%	213.56%
TOTAL LIABILITIES
Total Short-Term Liabilities	$305.4M	$23.84M	$147.4M
Total Long-Term Liabilities	$31.04M	$11.82M	$5.111M
Total Liabilities	$336.4M	$35.67M	$152.5M
YoY Change	1029.36%	-76.61%	504.42%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.713B	-$650.7M	-$832.6M
YoY Change	115.3%	-21.86%	-41.62%
Common Stock	$1.367B	$1.358B	$1.350B
YoY Change	2.91%	0.53%	-12.1%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$345.7M	$706.9M	$517.8M
YoY Change
Total Liabilities & Shareholders Equity	$603.2M	$1.155B	$1.083B
YoY Change	-38.18%	6.64%	80.76%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$1.062B	$45.71M	$38.80M
YoY Change	-2964.58%	17.82%	-2.82%
Depreciation, Depletion And Amortization	$270.0K	$286.0K	$355.0K
YoY Change	-25.0%	-19.44%	-13.41%
Cash From Operating Activities	$34.96M	$80.17M	$64.12M
YoY Change	-43.02%	25.02%	-12.99%
INVESTING ACTIVITIES
Capital Expenditures	$999.5M	$13.00K	$9.000K
YoY Change	-1135886.36%	44.44%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$999.5M	-$13.00K	-$9.000K
YoY Change	1135686.36%	44.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$92.50M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	399.1M	3.981M	-90.87M
YoY Change	-365.55%	-104.38%	-4210.04%
NET CHANGE
Cash From Operating Activities	34.96M	80.17M	64.12M
Cash From Investing Activities	-999.5M	-13.00K	-9.000K
Cash From Financing Activities	399.1M	3.981M	-90.87M
Net Change In Cash	-565.5M	84.14M	-26.76M
YoY Change	535.3%	-414.44%	-135.25%
FREE CASH FLOW
Cash From Operating Activities	$34.96M	$80.17M	$64.12M
Capital Expenditures	$999.5M	$13.00K	$9.000K
Free Cash Flow	-$964.5M	$80.16M	$64.12M
YoY Change	-1669.54%	25.02%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022Q1	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://www.ironwoodpharma.com/20230331#CollaborativeArrangementsMember
CY2023Q1	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://www.ironwoodpharma.com/20230331#CollaborativeArrangementsMember
CY2022Q1	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://www.ironwoodpharma.com/20230331#CollaborativeArrangementsMember
CY2023Q1	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://www.ironwoodpharma.com/20230331#CollaborativeArrangementsMember
CY2022Q4	us-gaap	Derivative Liability Statement Of Financial Position Extensible Enumeration DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2022#HedgingLiabilitiesCurrent
CY2023Q1	us-gaap	Derivative Liability Statement Of Financial Position Extensible Enumeration DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2022#HedgingLiabilitiesCurrent
CY2023Q1	us-gaap	Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList	http://fasb.org/us-gaap/2022#GainLossOnDerivativeInstrumentsNetPretax
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001446847
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q4	us-gaap	Derivative Liability Valuation Technique Extensible List DerivativeLiabilityValuationTechniqueExtensibleList	http://fasb.org/us-gaap/2022#ValuationTechniqueOptionPricingModelMember
CY2023Q1	us-gaap	Derivative Liability Valuation Technique Extensible List DerivativeLiabilityValuationTechniqueExtensibleList	http://fasb.org/us-gaap/2022#ValuationTechniqueOptionPricingModelMember
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-34620
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	IRONWOOD PHARMACEUTICALS, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-3404176
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	100 Summer Street
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 2300
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Boston
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02110
CY2023Q1	dei	City Area Code CityAreaCode	617
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	621-7722
CY2023Q1	dei	Security12b Title Security12bTitle	Class A common stock, $0.001 par value
CY2023Q1	dei	Entity Listing Par Value Per Share EntityListingParValuePerShare	0.001
CY2023Q1	dei	Trading Symbol TradingSymbol	IRWD
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	155346103
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	740342000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	656203000
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	115749000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	115458000
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9033000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7715000
CY2023Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	1250000
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1250000
CY2023Q1	us-gaap	Assets Current AssetsCurrent	866374000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	780626000
CY2023Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	485000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	485000
CY2022Q4	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	14589000
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6015000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6288000
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13674000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	14023000
CY2023Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	267909000
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	283661000
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	820000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	847000
CY2023Q1	us-gaap	Assets Assets	1155277000
CY2022Q4	us-gaap	Assets Assets	1100519000
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	118000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	483000
CY2023Q1	irwd	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	2874000
CY2022Q4	irwd	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	5258000
CY2023Q1	irwd	Accrued Expenses And Other Liabilities Current AccruedExpensesAndOtherLiabilitiesCurrent	17771000
CY2022Q4	irwd	Accrued Expenses And Other Liabilities Current AccruedExpensesAndOtherLiabilitiesCurrent	16700000
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3080000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3065000
CY2022Q4	us-gaap	Hedging Liabilities Current HedgingLiabilitiesCurrent	19000
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	23843000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25525000
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16105000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16599000
CY2023Q1	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	396653000
CY2022Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	396251000
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	11824000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9766000
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	75000000
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	75000000
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	155346103
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	155346103
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	154026949
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	154026949
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	155000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	154000
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1357359000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1348600000
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-650662000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-696376000
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	706852000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	652378000
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1155277000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1100519000
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	104061000
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	97529000
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	104061000
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	97529000
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12847000
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10822000
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	31117000
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	28861000
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	43964000
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	39683000
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	60097000
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	57846000
CY2023Q1	us-gaap	Interest Expense InterestExpense	1527000
CY2022Q1	us-gaap	Interest Expense InterestExpense	2341000
CY2023Q1	us-gaap	Investment Income Net InvestmentIncomeNet	7272000
CY2022Q1	us-gaap	Investment Income Net InvestmentIncomeNet	230000
CY2023Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	19000
CY2022Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	730000
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5764000
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1381000
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	65861000
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	56465000
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	20147000
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	17664000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	45714000
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	45714000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	38801000
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	38801000
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.30
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.25
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.25
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.21
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	154452000
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	157821000
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	186680000
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	189540000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	652378000
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1629000
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7131000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	45714000
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	706852000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	605911000
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1521000
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6089000
CY2022Q1	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	90489000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	38801000
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	517783000
CY2023Q1	us-gaap	Profit Loss ProfitLoss	45714000
CY2022Q1	us-gaap	Profit Loss ProfitLoss	38801000
CY2023Q1	us-gaap	Depreciation Depreciation	286000
CY2022Q1	us-gaap	Depreciation Depreciation	355000
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7131000
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	6089000
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-19000
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-417000
CY2022Q1	irwd	Fair Value Adjustment Of Convertible Note Hedging Instrument FairValueAdjustmentOfConvertibleNoteHedgingInstrument	-313000
CY2023Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	402000
CY2022Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	537000
CY2023Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	17052000
CY2022Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	14708000
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-14298000
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-18382000
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3669000
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-53000
CY2023Q1	irwd	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-349000
CY2022Q1	irwd	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-322000
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-27000
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-45000
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	705000
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-7117000
CY2023Q1	irwd	Increase Decrease In Accrued Research And Development Expense IncreaseDecreaseInAccruedResearchAndDevelopmentExpense	-2384000
CY2022Q1	irwd	Increase Decrease In Accrued Research And Development Expense IncreaseDecreaseInAccruedResearchAndDevelopmentExpense	-10454000
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-479000
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-483000
CY2023Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	758000
CY2022Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	3616000
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	80171000
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	64124000
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13000
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9000
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-13000
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9000
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3981000
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1622000
CY2022Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	92495000
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3981000
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-90873000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	84139000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-26758000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	657938000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	621864000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	742077000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	595106000
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	740342000
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	593371000
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	1735000
CY2022Q1	us-gaap	Restricted Cash RestrictedCash	1735000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	742077000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	595106000
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">1. Nature of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">Ironwood Pharmaceuticals, Inc. (“Ironwood” or the “Company”) is a gastrointestinal (“GI”) healthcare company dedicated to advancing the treatment of GI diseases and redefining the standard of care for GI patients. The Company is focused on the development and commercialization of innovative GI product opportunities in areas of significant unmet need, leveraging its demonstrated expertise and capabilities in GI diseases. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">LINZESS<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup><span style="white-space:pre-wrap;"> (linaclotide), the Company’s commercial product, is the first product approved by the United States Food and Drug Administration (the “U.S. FDA”) in a class of GI medicines called guanylate cyclase type C agonists (“GC-C agonists”) and is indicated for adult men and women suffering from irritable bowel syndrome with constipation (“IBS-C”) or chronic idiopathic constipation (“CIC”). LINZESS is available to adult men and women suffering from IBS-C or CIC in the United States (the “U.S.”), Mexico and Saudi Arabia and to adult men and women suffering from IBS-C or chronic constipation in Japan and IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup><span style="white-space:pre-wrap;"> to adult men and women suffering from IBS-C or CIC in Canada, and to adult men and women suffering from IBS-C in certain European countries. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company has strategic partnerships with leading pharmaceutical companies to support the development and commercialization of linaclotide throughout the world. The Company and its partner, AbbVie Inc. (together with its affiliates, “AbbVie”), began commercializing LINZESS in the U.S. in December 2012. Under the Company’s collaboration for North America with <span style="color:#212529;background:#ffffff;">AbbVie</span>, total net sales of LINZESS in the U.S., as recorded by <span style="color:#212529;background:#ffffff;">AbbVie</span>, are reduced by commercial costs incurred by each party, and the resulting amount is shared equally between the Company and <span style="color:#212529;background:#ffffff;">AbbVie</span>. Additionally, development costs are shared equally between the Company and AbbVie. The Company and AbbVie are exploring ways to enhance the clinical profile of LINZESS by studying linaclotide in additional indications, populations and formulations to assess its potential to treat various conditions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Outside of the U.S., the Company earns royalties as a percentage of net sales of products containing linaclotide as an active ingredient by the Company’s collaboration partners. AbbVie has an exclusive license from the Company to develop and commercialize linaclotide in all countries other than China (including Hong Kong and Macau), Japan and the countries and territories of North America (the “<span style="color:#212529;background:#ffffff;">AbbVie</span> License Territory”). In addition, <span style="color:#212529;background:#ffffff;">AbbVie</span> has exclusive rights to commercialize linaclotide in Canada as CONSTELLA and in Mexico as LINZESS. Astellas Pharma Inc. (“Astellas”), the Company’s partner in Japan, has an exclusive license to develop, manufacture, and commercialize linaclotide in Japan. AstraZeneca AB (together with its affiliates) (“AstraZeneca”), the Company’s partner in China, has the exclusive right to develop, manufacture, and commercialize products containing linaclotide in China (including Hong Kong and Macau) (the “AstraZeneca License Territory”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company has a collaboration and license option agreement (the “COUR Collaboration Agreement”) with COUR Pharmaceutical Development Company, Inc. (“COUR”), a biotechnology company developing novel immune-modifying nanoparticles to treat autoimmune diseases. The COUR Collaboration Agreement grants the Company an option to acquire an exclusive license to research, develop, manufacture and commercialize, in the U.S., products containing CNP-104, a potential treatment for primary biliary cholangitis, a rare autoimmune disease targeting the liver.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">These and other agreements are more fully described in Note 4, Collaboration, License, and Other Agreements, to these condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company is also advancing IW-3300, a GC-C agonist, for the potential treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome (“IC/BPS”) and endometriosis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company was incorporated in Delaware on January 5, 1998 as Microbia, Inc. On April 7, 2008, the Company changed its name to Ironwood Pharmaceuticals, Inc. To date, the Company has dedicated a majority of its activities to the research, development and commercialization of linaclotide, as well as to the research and development of its other product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#00ff00;"></span></p>
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of condensed consolidated financial statements in accordance with U.S. generally accepted accounting principles requires the Company’s management to make estimates and judgments that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. On an ongoing basis, the Company’s management evaluates its estimates, judgments and methodologies. Significant estimates and assumptions in the condensed consolidated financial statements include those related to revenue recognition; accounts receivable; useful lives of long-lived assets, impairment of long-lived assets, including goodwill; valuation procedures for right-of-use assets and operating lease liabilities; valuation procedures for the issuance and repurchase of convertible notes; balance sheet classification of convertible notes; fair value of derivatives; income taxes, including the valuation allowance for deferred tax assets; research and development expenses; contingencies and share-based compensation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ materially from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</p>
CY2023Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Reclassifications</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/>Certain prior period amounts have been reclassified to conform to current period presentation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;"></span></p>
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	45714000
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	38801000
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	46829000
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	39911000
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	154452000
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	157821000
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	186680000
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	189540000
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.30
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.25
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.25
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.21
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14010000
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16180000
CY2023Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	115700000
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	130000000.0
CY2023Q1	irwd	Accounts Receivable Net Of Accounts Payable Current And Noncurrent AccountsReceivableNetOfAccountsPayableCurrentAndNoncurrent	99900000
CY2022Q4	irwd	Accounts Receivable Net Of Accounts Payable Current And Noncurrent AccountsReceivableNetOfAccountsPayableCurrentAndNoncurrent	104400000
CY2022Q1	irwd	Threshold Percentage Of Collateralized Value ThresholdPercentageOfCollateralizedValue	1.02
CY2022Q1	irwd	Threshold Percentage Of Collateralized Value ThresholdPercentageOfCollateralizedValue	1.02
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	19000
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	19000
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9397000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	12268000
CY2023Q1	us-gaap	Interest Payable Current InterestPayableCurrent	1313000
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	188000
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7061000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4244000
CY2023Q1	irwd	Accrued Expenses And Other Liabilities Current AccruedExpensesAndOtherLiabilitiesCurrent	17771000
CY2022Q4	irwd	Accrued Expenses And Other Liabilities Current AccruedExpensesAndOtherLiabilitiesCurrent	16700000
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7100000
CY2023Q1	irwd	Other Accrued Liabilities Current Uninvoiced Vendor Liabilities OtherAccruedLiabilitiesCurrentUninvoicedVendorLiabilities	4200000
CY2023Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	2700000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4200000
CY2022Q4	irwd	Other Accrued Liabilities Current Uninvoiced Vendor Liabilities OtherAccruedLiabilitiesCurrentUninvoicedVendorLiabilities	3600000
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	1700000
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	1700000
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	627000
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	628000
CY2023Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	271000
CY2022Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	260000
CY2023Q1	us-gaap	Lease Cost LeaseCost	898000
CY2022Q1	us-gaap	Lease Cost LeaseCost	888000
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	757000
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	789000
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y2M12D
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y1M6D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.058
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.058
CY2021Q2	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	150000000.0
CY2023Q1	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	8000000.0
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	2309000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3126000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3189000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3252000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3317000
CY2023Q1	irwd	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	8285000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	23478000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4293000
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	19185000
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3080000
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16105000
CY2015Q2	us-gaap	Payments For Hedge Investing Activities PaymentsForHedgeInvestingActivities	21100000
CY2019Q3	us-gaap	Payments For Hedge Investing Activities PaymentsForHedgeInvestingActivities	25200000
CY2023Q1	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	3347000
CY2022Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	3749000
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	396653000
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	396251000
CY2023Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	1125000
CY2022Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	1804000
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	402000
CY2022Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	537000
CY2023Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	1527000
CY2022Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	2341000
CY2023Q1	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	90500000
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	4500000
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	203750000
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	3000000
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	201500000
CY2023Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	412750000
CY2023Q1	irwd	Long Term Debt Maturities Interest Payments LongTermDebtMaturitiesInterestPayments	12750000
CY2023Q1	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	3347000
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	396653000
CY2015Q2	us-gaap	Payments Of Derivative Issuance Costs PaymentsOfDerivativeIssuanceCosts	21100000
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7131000
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6089000
CY2023Q1	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	297000
CY2022Q1	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	-720000
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	7428000
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	5369000
	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	13100000
	irwd	Stock Repurchased And Retired During Period Average Price Per Share StockRepurchasedAndRetiredDuringPeriodAveragePricePerShare	11.47
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	20100000
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	17700000

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001558370-23-008092-index-headers.html	Edgar Link	pending
0001558370-23-008092-index.html	Edgar Link	pending
0001558370-23-008092.txt	Edgar Link	pending
0001558370-23-008092-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
irwd-20230331.xsd	Edgar Link	pending
irwd-20230331x10q.htm	Edgar Link	pending
irwd-20230331xex31d1.htm	Edgar Link	pending
irwd-20230331xex31d2.htm	Edgar Link	pending
irwd-20230331xex32d1.htm	Edgar Link	pending
irwd-20230331xex32d2.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
irwd-20230331_def.xml	Edgar Link	unprocessable
irwd-20230331_cal.xml	Edgar Link	unprocessable
irwd-20230331_lab.xml	Edgar Link	unprocessable
irwd-20230331_pre.xml	Edgar Link	unprocessable
irwd-20230331x10q_htm.xml	Edgar Link	completed
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IRWD
IRONWOOD PHARMACEUTICALS INC Stock $irwd

2023 Q2 Form 10-Q Financial Statement

#000155837023008092 Filed on May 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IRWD IRONWOOD PHARMACEUTICALS INC Stock $irwd

2023 Q2 Form 10-Q Financial Statement

#000155837023008092 Filed on May 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IRWD
IRONWOOD PHARMACEUTICALS INC Stock $irwd